Clinical Trial

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Study acronym: Toco-CoR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-01-27; most recent amendment 2026-03-30.
Status change: Recruiting → Active, Not Recruiting 2024-11-13
Status change: Not Yet Recruiting → Recruiting 2020-06-17
Trial Details
NCT Number NCT04245865
Lead Sponsor Vejle Hospital
Conditions Colorectal Cancer Metastatic
Enrollment 83 participants
Start Date 2020-06-26
Primary Completion 2025-03-31 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-03